Predicting major heart problems after coronary artery bypass grafting in people with heart failure
Official title: Risk Stratification of MACE Based on GDF-15 in Heart Failure Patients Who Undergoing Coronary Artery Bypass Grafting: an Observational Multicenter Prospective Study
Run by Tomsk National Research Medical Center of the Russian Academy of Sciences · NCT07480915 · Data updated 2026-11-12
This study will test whether a blood marker called GDF-15 taken before bypass surgery can help predict major heart events over the year after CABG in patients with chronic heart failure and coronary artery disease.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 160 (estimated) |
| Sponsor | Tomsk National Research Medical Center of the Russian Academy of Sciences Academic / other |
| Locations | 1 site (Tomsk, Tomsk Oblast) |
| Status | Recruiting |
| Started | March 4, 2026 |
| Main results expected | March 2027 |
| Study ends | March 2028 |
| Registry record updated | October 6, 2026 |
| Trial ID | NCT07480915 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with a documented diagnosis of chronic heart failure and coronary artery disease who are planned for isolated coronary artery bypass grafting and can provide informed consent and a preoperative blood sample are ideal candidates.
✕Probably not a fit
Patients with recent myocardial infarction or stroke, implanted cardiac devices, need for additional cardiac surgery, severe renal failure (GFR <30), active cancer, infiltrative or autoimmune cardiac disease, or acute infections were excluded and therefore are unlikely to benefit from the study findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
PROFILE-HF is a prospective, multicenter observational cohort of patients with chronic heart failure and coronary artery disease who are scheduled for coronary artery bypass grafting. At enrollment a preoperative blood sample will be taken and serum stored for measurement of GDF-15, with standardized processing and cold-chain transport to a central laboratory. Participants will be followed for 12 months for major adverse cardiovascular events (MACE) with one planned in-person visit at the end of follow-up or telephone contact if needed. Clinical care and treatments are managed according to standard practice and recorded but not altered by the study.
Why it matters
Potential benefit: If successful, the test could help identify patients at higher risk of major cardiac events after CABG so clinicians can target closer monitoring or tailored therapy.
How similar studies have gone: Biomarker approaches including GDF-15 have previously shown prognostic value in heart failure and coronary disease cohorts, but using preoperative GDF-15 specifically for CABG risk stratification has been less widely tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Heart Failure * Planned coronary artery bypass grafting Exclusion Criteria: * Myocardial infarction * Stroke * Presence of implanted devices; * Need for additional cardiac surgery other than coronary artery bypass grafting (valve repair, aneurysm); * Severe renal dysfunction (GFR \<30 ml/min/1.73 m2); * Severe comorbidities: active cancer; infiltrative cardiac diseases (sarcoidosis, amyloidosis, storage diseases); autoimmune diseases; acute infectious diseases and exacerbations of chronic somatic diseases.
Where it's running
-
Cardiology Research Institute, Tomsk National Research Medical Center Russian Academy of Sciences
Tomsk, Tomsk Oblast, Russia Recruiting
Study contacts
- Principal investigator: Alla A. Garganeeva, MD, PhD — Tomsk NRMC
- Study coordinator: Alla A. Garganeeva, MD, PhD
- Email: aag@cardio-tomsk.ru
- Phone: +7 (3822) 56 52 75
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pain relief after CABG: tafalgin versus morphine
This will test whether tafalgin relieves pain after coronary artery bypass surgery as well as morphine in adult patients.
-
Bypass surgery versus stents for people with weak heart pumping and blockages in multiple coronary arteries
This trial tests whether bypass surgery (CABG) or stents (PCI) lead to better survival, fewer major heart problems, and improved quality of life for adults with reduced left ventricular function (LVEF ≤40%) and multivessel coronary disease.
-
Cardiac rehabilitation cohort at Medicine Campus Davos to explore recovery
This project will follow adults coming to Hochgebirgsklinik Davos for cardiac rehabilitation to see how their heart health and recovery progress over time.
-
Using Apple Watch data to predict heart failure outcomes
This study is testing if data from Apple Watches can help predict heart failure problems and the chances of needing to go back to the hospital for patients with heart failure.
-
Comparing Aortix Device to Diuretics for Acute Heart Failure
This study is testing whether the Aortix device can help people with acute heart failure who aren't responding to diuretics feel better compared to standard treatment.
-
Myocardial Energetics Across Cardiovascular Disease Spectrum Using 31P-MRS
Researchers are testing whether phosphorus-31 magnetic resonance spectroscopy (31P-MRS) can map heart energy metabolism across healthy people and patients with various heart conditions.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.